摘要
目的探讨布林佐胺联合曲伏前列素治疗原发性开角型青光眼的临床疗效及安全性。方法选取2016年10月至2018年10月上海市杨浦区控江医院收治的原发性开角型青光眼100例患者,随机数字法分为常规组和观察组,各50例。常规组予以单一曲伏前列素治疗,观察组在常规组用药基础之上给予布林佐胺治疗,比较两组疗效、不良反应发生率及用药6个月后眼压。结果观察组治疗有效率显著高于常规组(94.00%vs.76.00%,P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。用药6个月后观察组眼压显著低于常规组(P<0.05)。结论原发性开角型青光眼治疗中采用布林佐胺联合曲伏前列素治疗效果显著且安全性较高。
Objective To investigate the clinical effect and safety of brinzolamine combined with travoprost in the treatment of primary open-angle glaucoma.Methods From October 2016 to October 2018,100 cases of primary open-angle glaucoma were admitted to the Kongjiang Hospital of Yangpu District,Shanghai.They were randomly divided into routine group and observation group,50 cases in each group.The routine group was treated with single travoprost,while the observation group was treated with brinzolamide plus travoprost.The effective rate,adverse reaction incidence,and intraocular pressure after 6 months of treatment were compared between the two groups.Results The effective rate of the observation group was significantly higher than the normal group(94.00%vs.76.00%,P<0.05).There was no significant difference in incidence of adverse reactions between the two groups(P>0.05).The intraocular pressure of the observation group was lower than the normal group after 6 months of treatment(P<0.05).Conclusion Brinzolam combined with travoprost is effective and safe in the treatment of primary open-angle glaucoma.
作者
陈佩媛
CHEN Peiyuan(Shanghai Yangpu District Kongjiang Hospital,Shanghai 200093,China)
出处
《大医生》
2019年第14期100-101,共2页
Doctor
